On August 16, 2019 Abbisko Therapeutics, a clinical-stage biopharmaceutical company focused on creating innovative medicine for unmet medical needs in China and around the world, reported that it has received regulatory approval from US FDA to initiate its Phase 1 trial for ABSK021, a CSF-1R small molecule inhibitor for treating multiple types of tumors, and expects to start dosing patients shortly (Press release, Abbisko Therapeutics, AUG 16, 2019, View Source;article_id=123 [SID1234556288]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ABSK021 is independently discovered and developed by Abbisko Therapeutics with full intellectual property rights worldwide. It is an orally administrated, highly potent, and selective small molecule inhibitor of CSF-1R with best-in-class drug-like properties. Through CSF-1R inhibition, ABSK021 could reprogram tumor-associate macrophages (TAMs) and other immune cells, modulate tumor microenvironment, and relieve tumor immunosuppression.

Based on its mechanism of action and a large number of preclinical findings, Abbisko is advancing ABSK021 into a Phase 1 clinical study in patients with advanced malignancies and Tenosynovial Giant Cell Tumors (TGCT) where TAMs are known to be likely contributors of tumorigenesis.